Click to enlarge the overview!

Amongst the numerous pathways implicated in cancer development, the PI3K/AKT/mTOR signalling pathway is highly active in cancer cells. Mutation or amplification of the PI3-kinase or AKT genes, as well as loss of function of PTEN protein, result in the activation of the mTOR pathway, which is associated with a poor prognosis in cancer, and therapy resistance.

Browse our complete PI3K / AKT / mTOR-related products range or click the image beside to display our interactive pathway!

Download Files

References:

• 1 - Yuan TL and Cantley LC. PI3K pathway alterations in cancer: variations on a theme. 2008. Oncogene 27:5497-510
• 2 - Yang WL et al. Regulation of Akt signaling activation by ubiquitination. 2010. Cell Cycle 9:487-97
• 3 - Zhao B. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. 2007. Genes Dev 21:2747-61
• 4 - Sakamaki JI et al. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. 2011. PNAS 108:6085-90
• 5 - Takahashi-Yanaga F and Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. 2008. Cell Signal 20:581-9
• 6 - Wullschleger S et al. TOR signaling in growth and metabolism. 2006. Cell 124:471-84
• 7 - De Benedetti A and Graff JR. eIF-4E expression and its role in malignancies and metastases. 2004. Oncogene 23:3189-99
• 8 - Wade M et al. The p53 orchestra: Mdm2 and Mdmx set the tone. 2010. Trends Cell Biol 20:299-309
• 9 - Chipuk JE et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. 2004. Science 303:1010-4
• 10 - Fu Z and Tindall DJ. FOXOs, cancer and regulation of apoptosis. 2008. Oncogene 27:2312-9